📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-04 12:06
343 analysed today
343
Today
133,232
All-time analysed
40,094
Positive
6,279
Negative
79,048
Neutral
7,743
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
27 announcements match the current filters (relevance ≥ 5).
Acutaas Chemicals Inaugurates OEB 4 Pilot Plant at Sachin for High-Potency API Intermediates
Acutaas Chemicals Limited (formerly Ami Organics Limited) has inaugurated a new pilot plant at its Unit 1 facility in Sachin, Surat on September 4, 2026. The plant includes a dedicated area designed for Occupational Exposure Band (OEB) 4 containment, allowing scale-up and development of highly potent intermediates for high-potency APIs (HPAPIs). The facility will also support R&D trials and validations for new pipeline products. While specific capex figures were not disclosed, this enhances the company's CDMO capabilities in higher-margin potent compounds against its TTM revenue base of Rs 843 Cr.
Confidence: HIGH
What changedAcutaas Chemicals has commissioned a specialized OEB 4 pilot plant at Sachin, Surat to expand R&D and scale-up capabilities for high-potency API intermediates.
Why it mattersOEB 4 containment capabilities allow the company to move up the value chain into complex, high-potency molecules, supporting long-term margins and CDMO client acquisition.
Inauguration Date: September 4, 2026Containment Standard: OEB 4Location: Unit 1 - Sachin, SuratCapex Outlay: not disclosedTTM Revenue Context: Rs 843 Cr
📅 Short termPositive for sentiment as it demonstrates ongoing R&D infrastructure build-up, though direct near-term revenue impact will depend on client trials and validation cycles.
📈 Long termStrengthens competitive moat in custom synthesis and CDMO for potent oncology/specialty drugs, potentially driving margin expansion over the next 2-3 years.
⚠ Risk flags
- Commercialization gestation timelines for HPAPI intermediates can be lengthy
- Capex outlay and exact capacity additions were not disclosed
Key Highlights
Inaugurated new state-of-the-art pilot plant at Unit 1 - Sachin, Surat on September 4, 2026
Equipped with dedicated Occupational Exposure Band (OEB) 4 containment infrastructure
Enables scale-up and commercial development of highly potent intermediates for HPAPIs
Capex and capacity additions for the pilot plant were not disclosed
👀 What to Watch
Track management commentary in upcoming quarterly calls regarding CDMO pipeline conversions, client validation timelines, and revenue contribution from high-potency molecules.
Acutaas Chemicals Sets Sep 17, 2026 Record Date for ₹2.50/Share Final Dividend
Acutaas Chemicals Limited has fixed Thursday, September 17, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹2.50 per equity share (50% on face value of ₹5) for FY 2025-26. The dividend is subject to shareholder approval at the upcoming 19th Annual General Meeting scheduled for September 24, 2026. Once approved, the payout will be completed within 30 days of the AGM declaration.
Confidence: HIGH
What changedAcutaas Chemicals announced the formal record date and AGM timeline for its FY26 final dividend payout.
Why it mattersConfirms the cash distribution timeline for eligible shareholders; the ₹2.50 payout represents a modest dividend yield relative to the current market price of ₹3,281.60.
Final dividend per share: Rs. 2.50/-Dividend percentage: 50%Face value: Rs. 5/-Record date: 17-Sep-2026AGM date: 24-Sep-2026
📅 Short termEx-dividend price adjustment will take place around September 16-17, 2026, with minimal impact on trading momentum given the low yield.
📈 Long termLimited; this is a standard corporate action reflecting regular cash distribution policy.
Key Highlights
Final dividend rate fixed at 50% or ₹2.50 per equity share of face value ₹5
Record date set for Thursday, September 17, 2026
19th Annual General Meeting (AGM) scheduled for Thursday, September 24, 2026
Payment to be credited within 30 days of shareholder approval at the AGM
👀 What to Watch
Investors seeking dividend eligibility must hold shares before the ex-dividend date preceding September 17, 2026, and track shareholder voting outcomes at the AGM on September 24, 2026.
Acutaas Subsidiary Inaugurates ~₹200 Cr Semiconductor Materials Plant in South Korea
Acutaas Chemicals' step-down subsidiary, Indichem Inc., has inaugurated its semiconductor materials plant in Gongju, South Korea. Acutaas Advance Material Limited holds a 75% stake in Indichem and has invested KRW 30 billion (approx. ₹200 crore), representing ~23.7% of Acutaas' TTM revenue of ₹843 crore. Completed in 11 months, the facility spans 16,513.7 sq. m. and utilizes a two-country model where chemicals are synthesised in India and refined to semiconductor grade (parts-per-billion purity) in Korea close to customer clusters.
Confidence: HIGH
What changedIndichem Inc. transitioned from construction to operational status with the inauguration of its Gongju semiconductor materials plant.
Why it mattersEnables Acutaas to scale high-margin semiconductor and display specialty chemicals by synthesizing in India and refining locally for Korean semiconductor giants.
Investment by Acutaas (AAML): KRW 30 billion (approx. ₹200 crore)Investment vs TTM revenue: ~23.7%Acutaas subsidiary equity stake: 75%Facility land area: 16,513.7 sq. m.Construction turnaround: 11 months
📅 Short termPositive sentiment driver highlighting disciplined project execution and entry into the high-value semiconductor supply chain.
📈 Long termHigh structural significance as commercialization of semiconductor chemicals provides product diversification away from pure pharma intermediates and unlocks new export revenue streams.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Customer qualification lead times in semiconductor-grade chemicals can be lengthy
- Rising goodwill amortisation / carrying value risks from overseas subsidiary investment
Key Highlights
Commissioned semiconductor chemicals plant at Gongju, South Korea, completed within 11 months of its September 29, 2025 groundbreaking.
Acutaas Advance Material Limited invested KRW 30 billion (approx. ₹200 crore) for a 75% stake in JV partner Indichem Inc.
Facility spans 16,513.7 sq. m. across three buildings including production block, HQ/R&D/pilot plant, and warehouse.
J & Materials Co. Ltd holds the remaining 25% stake under the joint venture agreement signed June 27, 2025.
👀 What to Watch
Track customer qualification cycles and commercial shipment ramp-up schedules in upcoming quarterly management commentaries.
Acutaas Chemicals Approves ₹212 Cr Capex for 81,000 MTPA Electronic Chemicals Plant
Acutaas Chemicals has approved a capital expenditure plan of up to ₹212 crore to set up a greenfield/brownfield manufacturing facility in Gujarat for new electronic grade chemicals. The proposed plant will have an annual capacity of up to 81,000 MT per annum and is scheduled to be completed by the end of FY 2027-28. The capex, representing ~25.1% of TTM revenue (₹843 crore), will be funded via internal accruals, bank financing, or other permissible methods. Additionally, the Board approved the re-appointment of two directors and extended the ESOS 2023 scheme to Indian subsidiary employees.
Confidence: HIGH
What changedThe Board approved a major ₹212 crore expansion into electronic grade chemicals and extended ESOS benefits to subsidiary staff.
Why it mattersThe ₹212 crore capex (~25.1% of TTM revenue) enters a high-growth, high-value specialty chemical segment (electronic/semiconductor grade), diversifying away from core pharma intermediates.
Capex Outlay: Up to Rs. 212 croresProposed Capacity: Upto 81,000 MT per annumCapex vs TTM Revenue: ~25.1%Target Commissioning: By the end of FY 2027-28AGM Date: September 24, 2026
📅 Short termPositive sentiment driver as the company formalizes entry into electronic chemicals, though operational impact is medium-to-long term.
📈 Long termEnhances revenue diversification and margin potential through electronic grade specialty chemical supplies by FY28.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Project execution and commissioning delays before FY28
- Funding mix impact on leverage if debt financed
Key Highlights
Approved capital expenditure of up to ₹212 crore for electronic grade chemicals in Gujarat
Proposed production capacity of up to 81,000 MT per annum (existing capacity: Nil)
Target completion timeline set for the end of FY 2027-28
Funding to be managed via internal accruals, bank debt, or other financing methods
19th AGM scheduled for September 24, 2026
👀 What to Watch
Track progress on land acquisition, environmental clearances, financing closure, and execution updates toward the FY28 target commissioning.
Acutaas Wins MeitY ECMS Incentive Approval for ₹256.47 Cr Electrolyte Project
Acutaas Chemicals Limited has received formal approval under the Ministry of Electronics and Information Technology's (MeitY) Electronics Components Manufacturing Scheme (ECMS). The approval applies to its Electrolyte Additives manufacturing business located at Jhagadia, Gujarat. Total cumulative project investment is ₹256.47 crores (~30.4% of TTM revenue), with ₹119.12 crores qualifying as eligible investment. Under the scheme, Acutaas is eligible to receive incentives of up to 25% on the eligible investment (approx. ₹29.78 crores) over a 5-year period ending in FY 2030-31.
Confidence: HIGH
What changedAcutaas secured MeitY approval under the ECMS scheme, entitling its battery electrolyte project to central government capital/production incentives.
Why it mattersThe subsidy improves capital efficiency and project return metrics for the company's high-value diversification into EV battery and electronics chemicals.
Cumulative project capex: Rs. 256.47 croresEligible ECMS investment: Rs. 119.12 croresCapex vs TTM revenue: ~30.4%Max incentive percentage: upto 25%Benefit period: up to FY 2030-31
📅 Short termPositive sentiment driver as formal government endorsement and fiscal incentives lower net investment outlays.
📈 Long termStrengthens competitiveness in import-substitution battery chemistry, enhancing operating leverage as commercial volumes scale through FY31.
⚠ Risk flags
- Incentive realization is subject to continuous compliance with scheme guidelines and investment milestones
- Ramp-up dependent on domestic and global EV battery demand
Key Highlights
Approval granted under ECMS by Project Management Agency Engineers India Limited on August 17, 2026
Cumulative investment under the Jhagadia project stands at ₹256.47 crores
Eligible investment approved under the scheme is ₹119.12 crores
Incentive of up to 25% on eligible capex (~₹29.78 crores) available over 5 years up to FY 2030-31
👀 What to Watch
Track the commercial production ramp-up of the Jhagadia electrolyte additives plant and verify whether incentive milestones are met in upcoming annual disclosures.
59.1% Revenue Growth in Q1 FY27; Battery Chemicals Commercial Supply Commences
Acutaas Chemicals reported a robust Q1 FY27 with revenue reaching ₹329.7 crore, a 59.1% YoY increase, primarily driven by a 76.5% surge in the Pharma Intermediates segment. The company has successfully transitioned from trial runs to commercial supply for its battery chemicals plant, targeting a rapid ramp-up. While the Specialty Chemicals segment saw a 10.6% YoY decline due to the deliberate phasing out of low-margin commodity chemicals, gross margins expanded by 466 bps to 57.9%. Management has maintained a full-year revenue growth guidance of 25% with stable margins.
Confidence: HIGH
What changedThe company has officially commenced commercial supply of battery chemicals and is actively shifting its Specialty Chemicals portfolio away from commodity products toward higher-margin semiconductor and battery materials.
Why it mattersThe shift towards CDMO and high-tech specialty chemicals (EV batteries/semiconductors) represents a structural move to higher-value products, which could sustain the current high P/E multiple if growth targets are met.
Q1 FY27 Revenue: ₹329.7 crYoY Revenue Growth: 59.1%Gross Margin: 57.9%Q1 Capex: ₹56 crQ1 Capex vs TTM Revenue: ~6.8%FY27 Growth Guidance: 25%
📅 Short termThe strong revenue beat and margin expansion in Q1 are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe successful commercialization of battery and semiconductor chemicals provides a new growth engine beyond traditional pharma intermediates, potentially diversifying the revenue base over the next 3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- 21% dependency on Chinese imports for raw materials
- High customer concentration in specific CDMO molecules
- Geopolitical tensions in the Gulf impacting logistics
Key Highlights
Q1 FY27 Revenue grew 59.1% YoY to ₹329.7 crore, representing ~40% of total TTM revenue in a single quarter.
Pharma Intermediates segment revenue jumped 76.5% YoY to ₹292.7 crore, now contributing ~89% of total revenue.
Gross margins expanded significantly by 466 bps YoY to 57.9% due to a better product mix.
Incurred ₹56 crore in capex during the quarter, with ₹41 crore focused on battery chemicals and maintenance.
Management reaffirmed 25% revenue growth guidance for FY27 despite geopolitical logistical challenges.
👀 What to Watch
Watch for the execution and volume ramp-up in the battery chemicals and semiconductor segments over the next 2-3 quarters to see if they can offset the planned phase-out of commodity chemicals.
59.1% Revenue Growth in Q1 FY27; EBITDA Margins Expand to 34.3%
Acutaas Chemicals reported a strong start to FY27 with revenue growing 59.1% YoY to ₹329.7 crore, primarily driven by the Advance Intermediates segment which grew 76.5%. EBITDA surged 122.1% to ₹113.1 crore, with margins expanding significantly by 970 bps to 34.3% due to better product mix and operational efficiencies. PAT increased 70.4% to ₹75 crore, despite a sharp drop in other income to ₹1.8 crore from ₹15.9 crore YoY. The management maintained a full-year revenue growth guidance of 25%, suggesting a potential conservative outlook given the strong Q1 performance.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, highlighting a significant jump in profitability and a shift in revenue mix towards Advance Intermediates.
Why it mattersThe sharp margin expansion indicates successful execution in the high-value CDMO business and improved operational efficiency, which could lead to a valuation re-rating if these levels are maintained.
Q1 FY27 Revenue: ₹329.7 croreYoY Revenue Growth: 59.1%EBITDA Margin: 34.3%Q1 PAT: ₹75 croreQ1 Revenue vs FY26 Revenue: 24.6%
📅 Short termThe stock may react positively to the strong YoY growth and significant margin expansion, although the sequential (QoQ) decline in PAT might temper enthusiasm.
📈 Long termThe structural shift towards CDMO and entry into semiconductor/battery chemicals provides a long-term growth runway, supported by a 25% guided CAGR.
⚠ Risk flags
- 21% dependency on Chinese imports for raw materials
- High customer concentration
- Significant sequential (QoQ) decline in PAT (44.2%)
Key Highlights
Revenue from Advance Intermediates grew 76.5% YoY to ₹292.7 crore, now comprising 88% of total revenue.
EBITDA margins expanded from 24.6% in Q1 FY26 to 34.3% in Q1 FY27, driven by operational leverage.
PAT grew 70.4% YoY to ₹75 crore, though it declined 44.2% on a sequential (QoQ) basis.
Specialty Chemicals segment saw a 10.6% YoY decline to ₹37 crore due to muted performance in commodity chemicals.
Management reaffirmed a 25% revenue growth guidance for the full year FY27.
👀 What to Watch
Monitor the sustainability of the 34.3% EBITDA margin in upcoming quarters, as it significantly exceeds the FY25 average of 23%. Watch for the commercialization progress of semiconductor chemicals and electrolyte additives which are expected to ramp up in FY26-27.
70.4% YoY PAT Growth in Q1 FY27; Revenue up 59.1% to ₹329.7 Cr
Acutaas Chemicals reported a strong YoY performance for Q1 FY27, with revenue increasing 59.1% to ₹329.7 cr and PAT rising 70.4% to ₹75.0 cr. EBITDA margins saw a significant expansion of 970 bps YoY to 34.3%, driven by a 466 bps improvement in gross margins. While YoY growth is robust, the company saw a sequential (QoQ) decline in revenue by 23.8% and PAT by 44.2%. Management has maintained a full-year revenue growth guidance of 25% with stable margins.
Confidence: HIGH
What changedAcutaas Chemicals reported its Q1 FY27 financial results, showing substantial YoY growth in scale and profitability but a sequential dip from the previous quarter.
Why it mattersThe significant margin expansion suggests a shift toward higher-value products or improved operational efficiency, which is critical for justifying the company's high P/E valuation of 96.5.
Q1 FY27 Revenue: ₹329.7 crYoY Revenue Growth: 59.1%Q1 Revenue vs TTM Revenue: 40.1%EBITDA Margin: 34.3%QoQ Revenue Growth: -23.8%PAT Margin: 22.7%
📅 Short termThe strong YoY growth and margin expansion are likely to be viewed positively by the market, although the sequential decline in earnings may lead to some consolidation.
📈 Long termThe company's transition into semiconductor and battery chemicals, alongside its established CDMO business, provides a structural growth narrative for the coming years.
⚠ Risk flags
- Significant sequential (QoQ) decline in revenue and profit
- High valuation (P/E 96.5) requires consistent high-growth execution
- 21% dependency on Chinese imports for raw materials
Key Highlights
Revenue from operations grew 59.1% YoY to ₹329.7 cr in Q1 FY27
EBITDA surged 122.1% YoY to ₹113.1 cr, with margins expanding to 34.3% from 24.6%
PAT increased 70.4% YoY to ₹75.0 cr, though it declined 44.2% sequentially from Q4 FY26
Gross margins improved to 57.9%, up 466 bps compared to the same quarter last year
Management reaffirmed 25% revenue growth guidance for the full year FY27
👀 What to Watch
Investors should monitor the ramp-up of the semiconductor and battery chemical segments, which are key to achieving the 25% annual growth guidance. It is important to track if the high EBITDA margins (34.3%) can be sustained throughout the year given the sequential volatility.
Q1 Revenue up 59% YoY to ₹329.7 Cr; PAT rises 70% to ₹75 Cr
Acutaas Chemicals (formerly Ami Organics) reported strong YoY growth for Q1 FY27, with consolidated revenue increasing 59% to ₹329.7 Cr compared to ₹207.2 Cr in the same quarter last year. Net profit grew 70% YoY to ₹75 Cr, though it declined sequentially from ₹134.3 Cr in Q4 FY26. The company disclosed a 10% dilution in its electrolyte subsidiary (ACEPL) following a preferential issue to A.R.Z Pharma Ltd. Additionally, a GST inspection was conducted at the Surat facility in June 2026, which management expects will have no material financial impact.
Confidence: HIGH
What changedThe company has transitioned to a higher revenue base YoY and introduced a strategic partner in its electrolyte subsidiary, while also undergoing a routine but notable regulatory inspection.
Why it mattersThe strong YoY growth validates the company's expansion into specialty chemicals and CDMO, though the sequential dip highlights the quarterly volatility inherent in large contract-based pharma businesses.
Revenue (Q1 FY27): ₹329.67 CrPAT (Q1 FY27): ₹75.00 CrYoY Revenue Growth: 59%QoQ Revenue Growth: -23.8%Material Cost % of Revenue: 50.3%
📅 Short termThe market is likely to react positively to the robust YoY growth, although the sequential decline and the mention of a GST search may lead to some caution.
📈 Long termThe company's structural shift toward semiconductor chemicals and battery electrolytes, supported by strategic partnerships, remains a key long-term growth driver.
⚠ Risk flags
- GST inspection outcome pending final assessment
- Sequential revenue decline of 23.8%
- High raw material dependency (50.3% of revenue)
Key Highlights
Consolidated revenue from operations grew 59% YoY to ₹329.67 Cr from ₹207.24 Cr.
Net profit for the quarter stood at ₹75.00 Cr, a 70% increase over the ₹44.01 Cr reported in June 2025.
Basic EPS improved to ₹9.07 compared to ₹5.41 in the year-ago period.
Shareholding in subsidiary Acutaas Chemicals Electrolytes Pvt Ltd diluted from 100% to 90% on May 19, 2026.
GST and Central Excise department conducted a search operation at the Surat facility on June 22-23, 2026.
👀 What to Watch
Investors should monitor the ramp-up of the electrolyte business following the strategic stake sale in ACEPL and watch for any further updates regarding the GST inspection outcome.
Acutaas Chemicals: CGST Anti-Evasion Search Concludes at Surat Facilities
Acutaas Chemicals Limited has reported the conclusion of a search operation by the Central Goods & Service Tax (CGST) & Central Excise Anti-evasion Department, Surat. The inspection, conducted under Section 67(2) of the CGST Act, 2017, took place at the company's registered office and manufacturing unit in Sachin, Surat. As of June 23, 2026, the search has concluded, and the company states that no official document or demand has been issued by the department. Management has clarified that the event has no material impact on the company's financial or operational performance.
Key Highlights
Search conducted by the Additional Commissioner of CGST & CE, Anti-evasion Department, Surat.
Inspection concluded on June 23, 2026, at approximately 10:45 a.m. following an initial start on June 22.
The search targeted both the Registered Office and the manufacturing unit situated at GIDC Sachin, Surat.
No official violation notice or document has been issued by the CGST department following the search.
Company confirms zero material impact on financials, operations, or other activities at this stage.
👀 What to Watch
Investors should remain cautious and watch for subsequent disclosures regarding any potential tax demands or penalties that may arise from this inspection. While current impact is nil, the involvement of the anti-evasion wing necessitates monitoring for further legal developments.
CGST Anti-Evasion Search Initiated at Acutaas Chemicals' Surat Facilities
The Central Goods & Service Tax (CGST) & Central Excise Anti-evasion Department, Surat, initiated a search and inspection at Acutaas Chemicals' registered office and manufacturing facility in Sachin, Surat, on June 22, 2026. The proceedings are being conducted under Section 67(2) of the CGST Act, 2017, with officials arriving around 1:45 p.m. While the company reports no immediate material impact on business operations or financials, the search is currently ongoing. Investors should await further disclosures regarding the nature of the investigation and any potential tax liabilities.
Key Highlights
Search initiated by CGST & CE Anti-evasion Department, Surat, on June 22, 2026, at approximately 1:45 p.m.
Inspection covers both the registered office and the manufacturing unit located at Sachin, Surat.
Action taken under Section 67(2) of the Central Goods and Services Tax Act, 2017.
Management states there is currently no material impact on financials, business operations, or other activities.
The search proceedings were reported as ongoing at the time of the regulatory filing.
👀 What to Watch
Investors should monitor the stock closely for updates on the conclusion of the search and any potential tax demands or penalties. Until the investigation is resolved and the financial impact is quantified, the stock may experience volatility.
Acutaas Chemicals Dilutes 10% Stake in Subsidiary ACEPL to A.R.Z Pharma for ₹5.83 Crore
Acutaas Chemicals Limited has reduced its stake in its subsidiary, Acutaas Chemicals Electrolytes Private Limited (ACEPL), from 100% to 90%. This dilution occurred as ACEPL issued 1,111 new equity shares to a strategic investor, A.R.Z Pharma Ltd, at a high valuation of Rs. 52,490 per share. The total capital being raised at the subsidiary level is approximately Rs. 5.83 crore, with 25% paid upfront and the balance due within 12 months. Acutaas Chemicals retains full management control of the subsidiary despite the stake reduction.
Key Highlights
Subsidiary ACEPL issued 1,111 equity shares to A.R.Z Pharma Ltd on a preferential basis.
Shares issued at a significant premium of Rs. 52,480 per share, totaling Rs. 52,490 per share.
Total transaction value is approximately Rs. 5.83 crore, with Rs. 1.46 crore called up immediately.
Acutaas Chemicals Limited's shareholding in ACEPL decreased from 100% to 90%.
The parent company retains full management and operational control of the subsidiary.
👀 What to Watch
Investors should note the high valuation at which the subsidiary raised capital, which serves as a positive benchmark for the company's electrolyte business. Monitor the strategic benefits and potential synergies arising from the partnership with Israel-based A.R.Z Pharma.
Acutaas Chemicals Outlines ₹1,000+ Cr Capex Plan and Dominant 50-90% Market Share in Key Segments
Acutaas Chemicals (formerly Ami Organics) has reported a strong performance with FY26 Pharma revenue reaching ₹11,741 Mn and total sales surpassing ₹10,000 Mn in 2025. The company is aggressively expanding with a ₹1,000+ Cr capex plan through FY30, focusing on high-entry-barrier markets like Semiconductor and Battery chemicals. It holds a dominant 50-90% global market share in key pharmaceutical intermediates and is the first Indian manufacturer of electrolyte additives. While the battery segment is yet to generate commercial revenue, it has 10+ products in the pipeline and 5+ customer validations.
Key Highlights
Pharma segment revenue reached ₹11,741 Mn in FY26 with 50-90% global market share in key intermediates.
Executing a ₹1,000+ Cr capex plan (FY23-FY30), including ₹220 Cr for battery chemicals and ₹200 Cr for semiconductors.
Pioneering as India's first electrolyte additives manufacturer and only domestic producer of photoresist chemicals.
Surpassed ₹10,000 Mn in total sales in 2025, rebranding from Ami Organics to reflect specialty chemical focus.
Installed 16 MW solar capacity to meet the majority of electricity requirements across key facilities.
👀 What to Watch
Investors should monitor the commercialization timeline of the battery and semiconductor segments as they represent high-margin growth levers. The company's dominant position in chronic therapy pharma intermediates provides a stable cash flow base to fund these high-tech expansions.
Acutaas Chemicals Reports Record FY26 PAT of ₹356 Cr; Guides 25% Revenue Growth for FY27
Acutaas Chemicals delivered a robust FY26 performance with revenue growing 33% YoY to ₹1,339.4 crores and PAT more than doubling to ₹356.4 crores. The company is successfully diversifying into high-growth verticals like battery chemicals and semiconductors, with two new battery products expected to commercialize in FY27. Management has provided a confident 25% revenue growth guidance for FY27, supported by a strong CDMO pipeline and a planned 10x expansion of R&D capabilities. Despite global supply chain volatility, the company achieved a high Q4 EBITDA margin of 42.4%.
Key Highlights
FY26 Revenue increased 33% YoY to ₹1,339.4 crores, with Q4 revenue rising 40.3% to ₹432.8 crores.
Full-year PAT reached a record ₹356.4 crores, representing a growth of over 100% compared to the previous year.
Q4 EBITDA margins expanded to 42.4%, driven by a 1,467 bps improvement in gross margins due to a better product mix.
Invested ₹190 crores in South Korea JV (Indichem) and ₹195 crores in domestic capex for battery chemicals and pilot plants.
Announced a 10x capacity expansion of the R&D center to support specialized divisions in pharma, semiconductors, and electronics.
👀 What to Watch
Investors should maintain a positive outlook given the strong earnings beat and clear 25% growth guidance. Monitor the successful commercialization of the battery chemical and semiconductor verticals as they evolve into independent growth engines by FY28.
Acutaas Chemicals Recommends Final Dividend of Rs 2.5 Per Share for FY 2025-26
The Board of Directors of Acutaas Chemicals Limited has recommended a final dividend of Rs 2.5 per equity share for the financial year 2025-26. This represents a 50% payout on the face value of Rs 5 per share. The dividend will be distributed across 8,18,71,122 equity shares, pending approval from shareholders at the upcoming 19th Annual General Meeting. Record and payout dates will be announced by the company in due course.
Key Highlights
Recommended a final dividend of Rs 2.5 per equity share for FY 2025-26
Dividend rate stands at 50% of the face value of Rs 5 per share
Total number of eligible equity shares is 8,18,71,122
Subject to shareholder confirmation at the 19th Annual General Meeting
👀 What to Watch
Investors should hold the stock to be eligible for the dividend and watch for the announcement of the record date. The 50% dividend payout reflects a positive return to shareholders for the fiscal year.
Acutaas Chemicals FY26 PAT Surges 122% to ₹3,564 Mn; Q4 Margins Hit Record 31%
Acutaas Chemicals (formerly Ami Organics) delivered exceptional FY26 results, with annual revenue rising 33% to ₹13,394 million. Net profit for the year surged 122% to ₹3,564 million, supported by a massive expansion in EBITDA margins to 35.9%. The company achieved its highest-ever quarterly PAT margin of 31% in Q4 FY26, driven by strong growth in the Pharma CDMO and Semiconductor businesses. Management has guided for a robust 25% revenue growth in FY27, focusing on high-growth verticals like battery chemicals.
Key Highlights
FY26 Revenue grew 33% YoY to ₹13,394 million, led by a 37.5% jump in Advance Intermediates.
Annual PAT surged 122.2% to ₹3,564 million, while Q4 PAT rose 114.1% YoY to ₹1,343 million.
EBITDA margins expanded significantly from 23.0% in FY25 to 35.9% in FY26.
Return on Equity (ROE) jumped to 32.5% in FY26 compared to 15.1% in the previous year.
Management provided a strong growth outlook of 25% revenue increase for FY27.
👀 What to Watch
The company demonstrates industry-leading margin expansion and high return ratios (ROCE of 39.3%). Investors should monitor the execution of the 25% growth guidance for FY27 as a key performance indicator.
Acutaas Chemicals Q4 PAT Surges 114% YoY to ₹1,343 Mn; FY27 Revenue Guidance at 25%
Acutaas Chemicals reported a stellar performance for Q4 FY26, with revenue growing 40.3% YoY to ₹4,328 million. Net profit (PAT) more than doubled, rising 114.1% YoY to ₹1,343 million, driven by significant margin expansion. EBITDA margins improved drastically to 42.4% from 27.5% in the previous year's quarter. For the full year FY26, the company achieved a PAT of ₹3,564 million, a 122.2% increase over FY25. Management has provided a confident outlook, guiding for 25% revenue growth in FY27.
Key Highlights
Q4 FY26 Revenue from operations grew 40.3% YoY to ₹4,328 million
Q4 PAT jumped 114.1% YoY to ₹1,343 million with record margins of 31.0%
EBITDA for the quarter rose 116% YoY to ₹1,835 million, with margins expanding to 42.4%
Full-year FY26 PAT reached ₹3,564 million, marking a 122.2% growth over FY25
Management guided for 25% revenue growth in FY27, focusing on Battery Chemicals and Semiconductors
👀 What to Watch
Investors should consider the stock's strong momentum and margin expansion as a sign of successful diversification into high-value sectors. The 25% growth guidance for FY27 provides clear visibility for future earnings and justifies a positive outlook.
Acutaas Chemicals Recommends Rs 2.50 Dividend; Indichem INC Named Material Subsidiary
Acutaas Chemicals Limited (formerly Ami Organics) has approved its audited financial results for the fiscal year ended March 31, 2026. The Board recommended a final dividend of Rs 2.50 per equity share (50% of face value), pending shareholder approval. A significant development is the classification of step-down subsidiary Indichem INC as a 'Material Subsidiary' based on its financial performance. The company also refreshed its audit team by appointing new internal and cost auditors for the 2026-27 fiscal year.
Key Highlights
Recommended a final dividend of Rs 2.50 per equity share of Rs 5 face value (50% payout).
Dividend to be distributed across 8,18,71,122 equity shares subject to AGM approval.
Indichem INC identified as a Material Subsidiary, indicating a significant contribution to consolidated financials.
M/s K. C Mehta & Co. LLP appointed as Internal Auditors for the financial year 2026-27.
Audited Standalone and Consolidated Financial Results for FY 2025-26 approved by the Board.
👀 What to Watch
Investors should note the dividend yield and the growing importance of the US-based subsidiary Indichem INC. Monitor the full financial statement for specific revenue and profit growth figures compared to the previous year.
Acutaas Chemicals Completes 75% Acquisition of South Korean Semiconductor Chemical Firm Indichem
Acutaas Chemicals, through its wholly owned subsidiary Acutaas Advance Material Limited, has completed the acquisition of a 75% controlling stake in South Korean firm Indichem Inc. Indichem is a newly incorporated entity specializing in the semiconductor chemicals industry, providing Acutaas with a strategic entry into this high-growth global market. The acquisition involved 300,000 shares at a par value of KRW 500 each plus a share premium. Indichem is currently constructing a manufacturing plant in South Korea, which is scheduled for commissioning by the end of the 2025 calendar year.
Key Highlights
Acquired 75% controlling stake (300,000 shares) in South Korean firm Indichem Inc.
Target entity operates in the specialized semiconductor chemicals industry.
Acquisition price set at KRW 500 per share par value plus applicable share premium.
Manufacturing plant in South Korea is slated for commissioning by the end of 2025.
Indichem Inc. now becomes a step-down subsidiary of Acutaas Chemicals Limited.
👀 What to Watch
This acquisition is a strategic move into the high-margin semiconductor value chain. Investors should monitor the timely commissioning of the South Korean facility by late 2025 as it will be the primary driver for revenue from this new segment.
Acutaas Chemicals Q3 FY26 PAT Jumps 133.7% to ₹106.2 Cr; Revenue Guidance Raised to 30%
Acutaas Chemicals reported a stellar Q3 FY26 with revenue growing 43% YoY to ₹393.2 crores, driven by a 47% surge in the Advanced Pharma Intermediates segment. The company achieved its highest-ever margins, with EBITDA margins expanding significantly to 38.3% due to a favorable product mix and operating leverage. Management has upgraded its full-year FY26 revenue growth guidance to 30% and EBITDA margin guidance to a range of 32-35%. Strategic expansions into battery and semiconductor chemicals are progressing, with a new battery chemicals block inaugurated in January 2026.
Key Highlights
Revenue from operations grew 43% YoY to ₹393.2 crores in Q3 FY26.
PAT crossed the ₹100 crore milestone, reaching ₹106.2 crores, a 133.7% YoY increase.
EBITDA margins expanded by 1,335 bps YoY to 38.3%, leading to an upgraded annual margin guidance of 32-35%.
Pharma Intermediates segment revenue rose 47% YoY to ₹351.1 crores, fueled by CDMO growth.
Inaugurated a new battery chemicals block at Jhagadia; commercial operations expected to ramp up from Q1 FY27.
👀 What to Watch
Investors should view the guidance upgrade and margin expansion as strong indicators of structural growth and improved product mix. The entry into high-growth battery and semiconductor chemical segments provides a long-term catalyst for valuation re-rating.
